Despite advancements in anti-vascular endothelial growth factor (VEGF) therapy, blindness remains common in NVG due to anterior chamber angle obstruction by rubeosis and fibrovascular proliferation, which blocks aqueous humor outflow [2–4]. This evidence concerns the gene VEGFA and blindness (disorder).